CollPlant Biotechnologies Ltd. (CLGN) financial statements and ratios from SEC XBRL: revenue $2.37M (TTM), net margin -484.6%, revenue growth 360.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.37M |
| Net Margin | -484.6% |
| Return on Equity | -188.9% |
| Current Ratio | 2.53 |
| Revenue Growth (YoY) | 360.4% |
| EPS Growth (YoY) | -35.2% |
| FCF Growth (YoY) | -35.2% |
| EV / EBITDA | 0.1 |
| Price / Book | 0.68 |
| Price / Sales | 1.74 |
| FCF Yield | -229.2% |
| Altman Z-Score | -18.52 (distress) |
| Sector P/E (Healthcare) | 21.6 |
CLGN overview · CLGN earnings · CLGN KPIs · CLGN investor relations · CLGN ownership · CLGN peers · CLGN filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.